Drug Profile

Ranibizumab biosimilar - Intas Biopharmaceuticals

Latest Information Update: 04 Jan 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Intas Biopharmaceuticals
Developer Intas Biopharmaceuticals; Intas Pharmaceuticals
Class Eye disorder therapies; Immunoglobulin fragments; Monoclonal antibodies
Mechanism of Action Vascular endothelial growth factor A inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase III Wet age-related macular degeneration

Most Recent Events

28 Dec 2021 Phase-III clinical trials in Wet age-related macular degeneration in Hungary (Intravitreous) (EudraCT2021-001970-41)
28 Sep 2021 Discontinued - Phase-III for Wet age-related macular degeneration in India (Intravitreous)
15 Oct 2013 Clinical trials in Wet age-related macular degeneration in India (Intravitreous)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com